Efficacy and safety of dapagliflozin were similar...

Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.

Abstract

SOURCE CITATION: Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142:734-47. 32795086.

Authors

Hao Q; Guyatt G

Journal

Annals of Internal Medicine, Vol. 174, No. 1,

Publisher

American College of Physicians

Publication Date

January 1, 2021

DOI

10.7326/acpj202101190-010

ISSN

1056-8751

Associated Experts

Gordon Guyatt

Professor, Faculty of Health Sciences

Visit profile

Labels

Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team